This study will assess how different oral formulations of ubrogepant move through the body in healthy adult participants under fasting and fed conditions.
BMI is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG.
History: of epilepsy, any clinically significant cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic, neurologic, or psychiatric disease or disorder, history of Raynaud's Phenomenon, or any uncontrolled medical illness.
History of any clinically significant sensitivity or allergy to any medication or food.
Crossover
Ubrogepant
DrugIRT Oral Tablet
Ubrogepant
DrugODT Oral Tablet
Number of Participants Experiencing Adverse Events
An adverse event is defined as any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCt) of Ubrogepant
AUCt of Ubrogepant
AUC From Time 0 to the Time Infinity (AUCinf) of Ubrogepant
AUCinf of Ubrogepant
Maximum Observed Plasma Concentration (Cmax) of Ubrogepant
Cmax of Ubrogepant
This trial is not recruiting at the moment. You can still explore other options:
